These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25778469)

  • 21. Genetic variants of nucleotide excision repair genes are associated with DNA damage in coke oven workers.
    Wang F; He Y; Guo H; Li J; Yang Y; Wu Z; Zheng H; Wu T
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):211-8. PubMed ID: 20056640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Dong Y; Liu JW; Gao YJ; Zhou T; Chen YM
    Genet Mol Res; 2015 May; 14(2):5390-8. PubMed ID: 26125734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
    Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls.
    Slyskova J; Naccarati A; Pardini B; Polakova V; Vodickova L; Smerhovsky Z; Levy M; Lipska L; Liska V; Vodicka P
    Mutagenesis; 2012 Mar; 27(2):225-32. PubMed ID: 22294771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variation in the nucleotide excision repair pathway and colorectal cancer risk.
    Berndt SI; Platz EA; Fallin MD; Thuita LW; Hoffman SC; Helzlsouer KJ
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2263-9. PubMed ID: 17119055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
    J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin.
    Lin M; Zhang Y; Li A; Tang E; Peng J; Tang W; Zhang Y; Lu L; Xiao Y; Wei Q; Yin L; Li H
    Oncotarget; 2015 Jun; 6(18):16774-85. PubMed ID: 25904054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
    Liu Y; Chen H; Chen L; Hu C
    Hepatogastroenterology; 2012 Jun; 59(116):977-80. PubMed ID: 22580644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.
    Stoehlmacher J; Ghaderi V; Iobal S; Groshen S; Tsao-Wei D; Park D; Lenz HJ
    Anticancer Res; 2001; 21(4B):3075-9. PubMed ID: 11712813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.
    Kweekel DM; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2005 Apr; 31(2):90-105. PubMed ID: 15847979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
    Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
    Madbouly KM; Hussein AM; Zeid A
    Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.